ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)

Market Cap	5.86B +75.7%
Revenue (ttm)	801.40M +49.4%
Net Income	177.17M +119.6%
EPS	1.12 +118.2%
Shares Out	157.39M
PE Ratio	33.24
Forward PE	21.65
Dividend	0.06 (0.17%)
Ex-Dividend Date	Nov 17, 2025

Volume	1,425,419
Average Volume	4,015,797
Open	36.80
Previous Close	37.24
Day's Range	36.80 - 37.70
52-Week Range	20.73 - 47.97
Beta	0.74
RSI	51.73
Earnings Date	Apr 24, 2026

About ChengDu ShengNuo Biotec

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. Che...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,450
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688117

Financial Performance

In 2025, ChengDu ShengNuo Biotec's revenue was 741.46 million, an increase of 62.57% compared to the previous year's 456.07 million. Earnings were 157.92 million, an increase of 215.70%.